allogeneic processed thymus tissue-agdc
| Brand name | Rethymic |
|---|---|
| Active ingredient | allogeneic processed thymus tissue-agdc |
| Strength | SEMI-QUANTITATIVE |
| Dosage form | For Suspension |
| Route | Implantation |
| Modality | Biologic |
| FDA approval | October 2021 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.